Kao Daniela, Lux Anja, Schwab Inessa, Nimmerjahn Falk
Institute of Genetics, Department of Biology, University of Erlangen-Nürnberg, Erwin-Rommelstr. 3, 91058, Erlangen, Germany.
Semin Immunopathol. 2014 May;36(3):289-99. doi: 10.1007/s00281-014-0427-7. Epub 2014 Apr 29.
B cells and B cell-derived autoantibodies play a central role in the pathogenesis of many autoimmune diseases. Thus, depletion of B cells via monoclonal antibodies such as Rituximab is an obvious therapeutic intervention and has been used successfully in many instances. More recently, novel therapeutic options targeting either the autoantibody itself or resetting the threshold for B cell activation have become available and show promising immunomodulatory and anti-inflammatory effects in a variety of animal models. The aim of this review is to summarize these results and to provide an insight into the underlying molecular and cellular pathways of these novel therapeutic interventions targeting autoantibodies and B cells and to discuss their value for human therapy.
B细胞和B细胞衍生的自身抗体在许多自身免疫性疾病的发病机制中起着核心作用。因此，通过利妥昔单抗等单克隆抗体消耗B细胞是一种显而易见的治疗干预措施，并且已在许多情况下成功应用。最近，针对自身抗体本身或重置B细胞激活阈值的新型治疗选择已经出现，并在多种动物模型中显示出有前景的免疫调节和抗炎作用。本综述的目的是总结这些结果，深入了解这些针对自身抗体和B细胞的新型治疗干预措施的潜在分子和细胞途径，并讨论它们在人类治疗中的价值。
